NEW CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR COMPOUND

NEW CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR COMPOUND

Provided are crystalline forms of a KRAS G12C inhibitor compound and to processes for their preparation. Furthermore, provided is pharmaceutical composition comprising said crystalline forms, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition can be used as a medi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: WILCKEN, Rainer, GERSPACHER, Marc, WARIN, Nicolas, LORTHIOIS, Edwige Liliane Jeanne, VAUPEL, Andrea, LOZAC'H, Marie-Anne, LIU, Bo, RIGOLLIER, Pascal, XUE, Lijun, GE, Heng, MACHAUER, Rainer, MURA, Christophe, STRANG, Ross, MEISTER, Tanja, COTESTA, Simona, MAH, Robert, STUTZ, Stefan, SCHNEIDER, Nadine, LEBLANC, Catherine
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Provided are crystalline forms of a KRAS G12C inhibitor compound and to processes for their preparation. Furthermore, provided is pharmaceutical composition comprising said crystalline forms, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition can be used as a medicament, in particular for the treatment of cancer, and KRAS G12C-mutant cancer.